InvestSMART

Neurotech International Limited (ASX: NTI) - Announcements

- Current share price for NTI : $0.019

ASX company news and announcements for Neurotech International Limited (NTI) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurotech International Limited (NTI) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurotech International Limited (NTI), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurotech International Limited (NTI)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$31 Change of Director's Interest Notice 8 May 2024 1:58PM $0.075 $0.019 fallen by 74.67%
$31 Investor Webinar on Rett Syndrome Clinical Trial Results 6 May 2024 9:35AM $0.091 $0.019 fallen by 79.12%
$31 Investor Presentation 6 May 2024 9:34AM $0.091 $0.019 fallen by 79.12%
$31 Rett Syndrome Phase I/II trial shows significant benefits 6 May 2024 9:34AM $0.091 $0.019 fallen by 79.12%
$31 Trading Halt 3 May 2024 9:14AM $0.091 $0.019 fallen by 79.12%
$31 Neurotech Receives $10 Million in Placement Funds 24 Apr 2024 6:43PM $0.090 $0.019 fallen by 78.89%
$31 Notification regarding unquoted securities - NTI 24 Apr 2024 6:19PM $0.090 $0.019 fallen by 78.89%
$31 Secondary Trading Notice 24 Apr 2024 6:11PM $0.090 $0.019 fallen by 78.89%
$31 Application for quotation of securities - NTI 24 Apr 2024 6:09PM $0.090 $0.019 fallen by 78.89%
$31 Quarterly Activities/Appendix 4C Cash Flow Report 23 Apr 2024 9:38AM $0.092 $0.019 fallen by 79.35%
$31 Initial Director's Interest Notice 19 Apr 2024 12:39PM $0.095 $0.019 fallen by 80%
$31 Final Director's Interest Notice 19 Apr 2024 12:35PM $0.095 $0.019 fallen by 80%
$31 Proposed issue of securities - NTI 19 Apr 2024 9:23AM $0.095 $0.019 fallen by 80%
$31 Board Changes 19 Apr 2024 9:19AM $0.095 $0.019 fallen by 80%
$31 Investor Presentation 17 Apr 2024 10:02AM $0.105 $0.019 fallen by 81.90%
$31 Proposed issue of securities - NTI 17 Apr 2024 9:51AM $0.105 $0.019 fallen by 81.90%
$31 Neurotech Completes $10 Million Capital Raise 17 Apr 2024 9:51AM $0.105 $0.019 fallen by 81.90%
$31 Positive Top-Line Rett Syndrome Clinical Trial Results 17 Apr 2024 9:50AM $0.105 $0.019 fallen by 81.90%
$31 Phase II/III ASD Trial Successfully Meets Primary Endpoint 17 Apr 2024 9:50AM $0.105 $0.019 fallen by 81.90%
$31 Investor Webinar on Clinical Trial Results 16 Apr 2024 4:26PM $0.105 $0.019 fallen by 81.90%
$31 Trading Halt 15 Apr 2024 9:43AM $0.105 $0.019 fallen by 81.90%
$31 Proposed issue of securities - NTI 10 Apr 2024 3:41PM $0.105 $0.019 fallen by 81.90%
$31 Strategic Partnership with Fenix Innovation Group 10 Apr 2024 3:32PM $0.105 $0.019 fallen by 81.90%
$31 Last Patient Completes Treatment in NTIASD2 Clinical Trial 10 Apr 2024 8:22AM $0.100 $0.019 fallen by 81%
$31 Change in substantial holding 27 Mar 2024 5:51PM $0.105 $0.019 fallen by 81.90%

151 - 175 of 700 results

Page 7 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.